UK Cancer/Tumor Profiling Market (2022-2027)

RESEARCH METHODOLOGY

This study involved four major activities in estimating the current size of the cancer tumor profiling market. Exhaustive secondary research was conducted to collect information on the market, its peer markets, and the broader precision-oncology ecosystem. The findings, assumptions, and market sizing estimates were then validated through primary research with participants across the value chain. Both top-down and bottom-up approaches were used to estimate the complete market. Following this, data triangulation was applied to finalize the market size and the values of individual segments and subsegments.

Secondary Research

Secondary research was used to identify and gather information for this extensive technical, market-oriented, and commercial study. Public-sector sources included the US Food and Drug Administration (FDA), National Institutes of Health (NIH), National Cancer Institute (NCI), National Center for Biotechnology Information (NCBI), Centers for Disease Control and Prevention (CDC), World Health Organization (WHO), International Agency for Research on Cancer (IARC), Global Cancer Observatory (GLOBOCAN), European Medicines Agency (EMA), European Commission, and relevant national health ministries and cancer registries.

Company and industry sources included annual reports, SEC and other regulatory filings, investor presentations, earnings releases, product catalogs, regulatory databases, company websites, scientific publications, clinical trial registries, peer-reviewed journals, and publications from pathology, genomics, oncology, and laboratory medicine associations. These sources were used to identify major participants, product and service portfolios, regulatory approvals, installed sequencing and pathology capabilities, test volumes, oncology revenue exposure, partnerships, clinical-trial activity, regional presence, technology adoption, and market developments.

Secondary data were analyzed to estimate the overall cancer tumor profiling market and to construct preliminary splits by product and service, technology, sample type, application, cancer type, end user, and region. The resulting estimates were subsequently validated and refined through primary research.

Primary Research

In-depth interviews were conducted with primary respondents, including executives of diagnostics and life-science companies, laboratory directors, molecular pathologists, oncologists, sequencing specialists, product managers, business-development leaders, clinical-trial professionals, and subject-matter experts. Interviews were conducted across both the supply and demand sides to validate market definitions, adoption levels, average selling prices, test volumes, technology mix, regional variation, end-user behavior, growth assumptions, and competitive positioning:

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The global cancer tumor profiling market was estimated through multiple complementary approaches. A detailed market-engineering model was used to estimate and validate the overall market and each segment. The process combined company-level revenue analysis, product and service mapping, test-volume assessment, installed-base evaluation, average selling price analysis, end-user demand estimation, and regional adoption patterns. The research methodology used to estimate the market size includes the following:

Cancer Tumor Profiling Market : Top-Down and Bottom-Up Approach

Data Triangulation

After estimating the overall market through the market-size estimation process, the total market was split into the defined segments and subsegments. To complete the market-engineering process and arrive at the final statistics, data triangulation was employed. The process examined factors and trends from both the demand and supply sides and reconciled company revenues, test volumes, installed systems, consumable pull-through, service revenue, technology adoption, cancer incidence, biomarker-testing patterns, and regional market conditions.

The final estimates were checked for consistency across all dimensions. For example, the product and service totals were reconciled with technology, sample type, application, cancer type, end user, and regional totals. Company-share estimates were also compared with the independently derived global market size to ensure that no major revenue pools were omitted or double-counted.

Key Stakeholders

Geographic Analysis

• Further breakdown of the Rest of Europe cancer/tumor profiling market, by country

• Further breakdown of the Rest of Asia Pacific cancer/tumor profiling market, by country

Company Information

• Detailed analysis and profiling of additional market players (up to five)

• Further breakup of additional Asia Pacific countries by offering, deployment mode, enterprise size, application, and vertical

• Further breakup of additional Middle Eastern & African countries by offering, deployment mode, enterprise size, application, and vertical

Segment Analysis